Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abolished, acceptabletolerability, accreted, accrual, added, adenocarcinoma, affirmed, aggressive, AIA, aim, allelic, Allen, anagrelide, Analyst, andcommercialization, andour, andxenograft, anumber, appealedthe, argued, asgrowth, aspiration, Avastin, Beisheim, Big, biomedical, bond, Booz, breastcancer, burden, byprescription, byViaCyte, cannotpredict, capecitabine, carboplatin, Chicago, choice, chosen, CIRM, cisplatin, cleaved, clinicalresearch, clinicaltesting, compelling, composition, concept, contractor, Cooley, coordinated, cosmetic, count, Covance, CPMP, cranial, crizotinib, cytoreductive, database, Ddirectly, deal, debulking, decade, decisionfrom, decisionsin, deep, deficiency, Deutsche, disburse, disbursement, discontinuation, discontinue, discontinued, discontinuing, disorder, divest, divestiture, divesture, dosage, doublet, drugdiscovery, dysfunction, Earlham, Eastern, ECJ, elasticity, Elevated, EMA, endothelial, endpoint, Epidemiology, epidermal, erlotinib, essentialthrombocythemia, estrogen, eventually, extinguishment, FDAand, follicle, forfeited, forgiven, forother, forproduct, frequently, fundamental, gave, gemcitabine, Germany, Godward, graham, Greenpeace, growthin, growthof, half, Hamilton, headed, hemorrhagic, Herceptin, Hofstra, hydroxyurea, imaging, inassociation, incidence, incident, includingradiation, indrug, inflammatory, infusion, ingredient, inside, Interbank, Interferencesreversed, interferon, InterMune, intolerance, intolerant, invasive, Ipsen, ixabepilone, john, judicial, Justice, kinase, lackthereof, lenalidomide, leveraging, LIBOR, ligand, mayreceive, meaningful, Melanie, monotherapy, morbidity, MPL, mutant, mutation, myeloid, myeloproliferative, Nallicheri, native, neurocognitive, neurotoxicity, newmanufacturing, noncompetitive, nonspecific, Nordisk, North, Northeastern, Notably, Novo, nutraceutical, nutritional, obesity, ofproduct, oftissue, Orexigen, orthotopic, Otto, ourproduct, overalternative, owed, palliate, passed, patentabilityof, patentson, pemetrexed, permeability, PFS, pharma, pharmacologicalactivity, pioneering, platelet, polycythemia, poorly, Pritzker, profile, progesterone, proliferationin, promulgated, Proteolix, pulmonology, radiation, radiosurgery, rapidly, reagent, rebuild, reinitiating, remanded, repaid, resection, retrospectively, RIBBON, rightsto, Roche, Rosenfield, roughly, SA, salvage, sample, scarlett, secondary, SEER, shipped, shrinkage, sinceSeptember, sizable, slower, Southwestern, SRS, stability, stabilization, stable, standing, startup, statistical, stereotactic, stratify, subpopulation, summary, supplier, surgery, surgical, suspension, switch, symptomatic, synergistic, synergistically, technologyfor, Tercica, terminology, thalidomide, themeasurement, thePatent, therelevant, theWisconsin, Thomson, thought, thrombocytopenia, thrombotic, tight, tocommence, toearlier, toserve, trastuzumab, trialsand, triple, unamortized, unanticipated, unavailability, unexpected, unforeseen, unformulated, unregistered, unsuitable, upheld, valueof, veterinary, WBRT, WHU
Removed:
abnormally, accessory, accompanied, activate, activated, addressing, administrator, adult, advancing, afford, aging, agree, altering, AML, Amplification, ancillary, antigen, antisense, appointed, area, Arizona, attached, attack, banked, beef, behavior, billion, biochemical, biodistribution, Biosensor, birth, bladder, block, bloodstream, boost, borne, broadly, building, Cambrex, capable, carcinoma, cardiac, cardiovascular, cattle, chain, chemical, chemically, chromosomal, claimed, clock, clone, coding, collagen, collection, commentary, composed, concentrated, concluding, conduction, congestive, continuously, contractile, contracting, Convention, cooperate, cooperated, cooperation, corrected, covalently, created, cryopreserved, cytoplasm, daily, dairy, damaged, defense, degeneration, degradation, degraded, delaying, delivering, dependence, designate, desired, destructive, detrimental, device, devoted, diabetic, diagnosing, differentiate, differentiated, disabled, diseased, dismissed, diversion, Dolly, donated, donor, dosing, Duke, efficient, egg, electrical, ELISA, embryo, encounter, energy, engineered, engraft, engraftment, enhance, Enlarged, enucleated, enzymatic, essentially, exacerbate, explore, exposing, eye, family, faster, feasibility, female, fertilization, fetal, filled, fix, food, force, formation, foundational, Fusion, generation, genetically, genomic, glucose, graft, great, greenwood, grow, gut, harmful, harming, Harvard, healing, hematology, Histological, hope, Ian, ideal, immortal, immortality, immunity, immunogenicity, Immunology, Immunomic, ImmunoSorbent, impairing, implantation, implanted, implementation, Importantly, impractical, inability, incorporate, indefinite, infarction, informed, inhibitory, injected, injection, insulating, insulation, interaction, interim, intermittent, interpreting, introduce, introduced, isolating, Jane, Junior, jurisdiction, Katharine, kidney, kill, LAMP, largest, Lebkowski, left, legislation, lesion, lifespan, light, limiting, live, livestock, locomotor, longest, Lonza, losing, Lutheran, lymphoproliferative, lysosomal, macular, mainstay, margin, marker, matrix, mature, McKinsey, meat, mediated, membrane, Merck, merged, metabolic, mice, milk, Mitochondrial, modulate, Morgan, mortal, myelin, myelinated, myocardial, narrowly, neuronal, Neuroscience, neurotrophic, NIH, nonfunctional, NPS, objectionable, offspring, okarma, ordinary, Oregon, overgrowth, Pacific, pain, palmitoyl, par, paralyzed, partly, PCR, people, permanently, pharmacodynamic, pharmacokinetic, pharmacological, pill, pluripotency, pluripotent, poison, polymerase, pork, Portland, postpone, poultry, predicted, premium, presence, primitive, Princeton, profiting, progeny, prohibit, prohibition, proliferate, properly, Proposition, prostate, publicity, published, pulsed, question, rapid, rat, ratio, reaction, reconstituted, reexamined, regenerate, regulated, reject, relapsed, released, remodeling, removed, removing, repeat, repeatedly, replicate, replicative, reprogram, Reprogramming, requested, researching, reset, resource, restoring, retained, reverse, ribonucleic, Rice, robust, Rorer, Roslin, scalable, scalably, scaled, scar, screen, selecting, senescent, serial, sheep, shorten, showed, showing, social, Society, somatic, sparing, Spink, spread, stake, structural, studied, subsequently, suffering, sugar, suitable, suppressor, surface, synthesized, Syracuse, TBT, teach, teaching, telephone, Telomeric, therapeutically, thiophosphoramidate, thoracic, tolerizing, toxicology, Trademark, transcriptase, transferred, Transgenic, transiently, transplantation, transplanted, TRAP, uncontrolled, undifferentiated, unit, unpatentable, upregulate, Upregulation, urine, utilizing, vaccination, valve, ventricular, voiced, Walkersville, weekly, weight, Wilmut, wire, wound
Filing tables
Filing exhibits
- 10-K Annual report
- 10.1 Form of Indemnification Agreement
- 10.27 Employment Agreement Between the Registrant and Graham Cooper
- 10.29 Transition and Separation Agreement Between the Registrant
- 10.30 Separation Agreement Between the Registrant and Jane S. Lebkowski
- 10.31 Consulting Agreement Between the Registrant and Jane S. Lebkowski
- 10.32 Employment Agreement Between the Registrant and Stephen N. Rosenfield
- 10.36 Office Lease Agreement by and Between the Registrant and Exponent Realty, LLC
- 21.1 List of Subsidiaries
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Chief Executive Officer Pursuant to Form of Rule 13A-14(A)
- 31.2 Certification of Chief Financial Officer Pursuant to Form of Rule 13A-14(A)
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350
Related press release
GERN similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statement (Form S-3 No. 333-171611) and in the related prospectuses and prospectus supplements; | |
2) | Registration Statement (Form S-3 No. 333-168974) and in the related prospectuses and prospectus supplements; | |
3) | Registration Statement (Form S-3 No. 333-164246) and in the related prospectuses and prospectus supplements; | |
4) | Registration Statement (Form S-3 No. 333-160498) and in the related prospectuses and prospectus supplements; | |
5) | Registration Statement (Form S-3 No. 333-159288) and in the related prospectuses and prospectus supplements; | |
6) | Registration Statement (Form S-3 No. 333-147018) and in the related prospectuses and prospectus supplements; | |
7) | Registration Statement (Form S-8 No. 333-174350) pertaining to the 2011 Incentive Award Plan, the 2002 Equity Incentive Plan, the 1996 Directors’ Stock Option Plan and the 1992 Stock Option Plan; | |
8) | Registration Statement (Form S-8 No. 333-167349) pertaining to the 2002 Equity Incentive Plan; | |
9) | Registration Statement (Form S-8 No. 333-161035) pertaining to the 2002 Equity Incentive Plan and the 1996 Employee Stock Purchase Plan; | |
10) | Registration Statement (Form S-8 No. 333-152725) pertaining to the 2002 Equity Incentive Plan; | |
11) | Registration Statement (Form S-8 No. 333-145042) pertaining to the 2002 Equity Incentive Plan; | |
12) | Registration Statement (Form S-8 No. 333-136330) pertaining to the 2002 Equity Incentive Plan and the 2006 Directors’ Stock Option Plan; | |
13) | Registration Statement (Form S-8 No. 333-107276) pertaining to the 1996 Directors’ Stock Option Plan and the 1996 Employee Stock Purchase Plan; and | |
14) | Registration Statement (Form S-8 No. 333-70414) pertaining to the 1992 Stock Option Plan; |
of Geron Corporation of our reports dated March 7, 2012, with respect to the consolidated financial statements of Geron Corporation and the effectiveness of internal control over financial reporting of Geron Corporation, included in this Annual Report (Form 10-K) of Geron Corporation for the year ended December 31, 2011.
/s/ Ernst & Young LLP
Redwood City, California
March 7, 2012